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Introduction
First described in 1941,1 ataxia–telangiectasia (A-T) is a 
rare, autosomal recessive disorder with myriad characteris-
tics, most notably cerebellar degeneration, telangiectasias, 
immunodeficiency, and cancer susceptibility.2 The age of 
onset and rate of disease progression can vary widely, with 
typical onset of ataxia and telangiectasias at 1–4 years of 
age and 6 years of age, respectively.3 Average life expec-
tancy for A-T patients is 26 years,4 and the most common 
causes of death are chronic lung disease and cancer.2
Following extensive molecular and genetic evaluation, 
the genetic defect responsible for A-T was localized to 
chromosome 11 in 1988,5 and ATM was subsequently iden-
tified as the culprit gene in 1995.6 Although the molecular 
mechanisms of A-T pathophysiology are not fully eluci-
dated, ATM is known to play a critical role in regulation of 
the cell cycle, apoptosis, and response to DNA damage.7 
Given the critical importance of the ATM gene in cellular 
function and DNA repair, it is clear that A-T patients are at 
high risk for various cancers, and the risk of malignancy is 
estimated at 61–184 times greater than the general 
population.8
Although several reports have demonstrated a clear link 
between A-T and hematological malignancies, an associa-
tion with solid tumors is less established. Here, we describe 
the first reported case of a retroperitoneal tumor arising in a 
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patient with A-T. The mass was suspicious for a retroperi-
toneal sarcoma, but proved to be an extramedullary hemat-
opoietic pseudotumor after thorough radiographic and 
pathologic evaluation. To our knowledge, this is the first 
reported case of extramedullary hematopoietic pseudotu-
mor in an A-T patient and highlights the potential changing 
spectrum of neoplasms in A-T patients who are enjoying a 
longer lifespan because of improvements in multimodality 
care.
Case report
The patient is a 26-year-old woman with a childhood diag-
nosis of A-T, who suffers from the typical manifestations of 
the disease, including spastic paresis and frequent pulmo-
nary infections as well as insulin-resistant diabetes melli-
tus, polycystic ovarian syndrome, osteopenia, and 
non-alcoholic steatohepatitis. She provided written 
informed consent for her case information to be published 
in the medical literature. It was during a hepatic ultrasound 
for evaluation of her liver disease that an incidental left ret-
roperitoneal mass was discovered. Sonographic images of 
the abdomen demonstrated a 5.5 cm hypoechoic mass with 
internal vascularity in the left perirenal space which was 
potentially suspicious for malignancy (Figure 1(a)).
Further evaluation with a gadolinium-enhanced mag-
netic resonance imaging (MRI) revealed a 4.9 ×2.9 × 5.1 cm 
enhancing retroperitoneal mass with T2 hyperintensity 
which exerted mass effect on the left kidney (Figure 1(b)). 
In addition, MRI demonstrated heterogeneous enhance-
ment, restricted diffusion, and invasion into Gerota’s fas-
cia, all of which were concerning for malignancy (Figure 
1(c)).
An initial percutaneous biopsy was non-diagnostic, so 
the patient was referred for surgical evaluation. Computed 
tomography (CT) of the chest, abdomen, and pelvis, 
obtained for formal staging evaluation and surgical plan-
ning, revealed no evidence of metastases and confirmed the 
MRI findings of an extra-renal mass abutting the kidney 
with no clear evidence of invasion of the renal parenchyma 
Figure 1. Results of initial imaging evaluation. (a) Longitudinal ultrasound image demonstrating an oval hypoechoic mass superficial 
to the left kidney with mild mass effect on the left kidney. (b) Axial T2 fat saturation MRI shows the lesion as a fluid signal oval 
mass exerting mass effect upon the left kidney. Extension of intermediate signal along the left kidney in the perirenal space is also 
seen. (c) Axial T1 fat saturation MRI demonstrating heterogeneous, predominantly peripheral, and progressive enhancement of 
the left perirenal mass. The mass extends laterally beyond the posterior renal fascia and invades the intercostal musculature (white 
arrow). (d) Axial image from a subsequent CT of the abdomen with IV contrast shows loss of the fat place between the intercostal 
musculature and the low-density left perirenal mass.
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(Figure 1(d)). A repeat image-guided needle biopsy was 
performed, but was again non-diagnostic despite several 
expert consultations. The biopsy material consisted of 
abundant myxoid stroma with a paucicellular proliferation 
of spindle to stellate cells, rare larger atypical cells with 
hyperchromatic nuclei, and background chronic inflamma-
tion. Immunohistochemical stains for MDM2, CDK4, kera-
tin, desmin, SOX10, CD34, and MUC4 were negative, and 
FISH testing was negative for MDM2 gene amplification. 
The lack of staining for MDM2 and CDK4, as well as the 
negative FISH result, argued against a diagnosis of well-
differentiated liposarcoma. Overall, the findings were non-
specific, and the lesion was unable to be classified beyond 
a morphologically low-grade spindle cell neoplasm.
Given the patient’s significant comorbid conditions 
including restrictive lung disease, frailty, and dependent 
functional status (with corresponding high risk for post-
surgical complications), the decision was made initially to 
observe the mass with active surveillance; 3 months after 
the second biopsy, repeat MRI showed interval tumor 
enlargement with irregular enhancement, thickening of 
Gerota’s fascia, and new mass effect on the abdominal wall 
(Figure 2).
Based on the follow-up MRI results, the decision was 
made to proceed with surgical excision using a left subcos-
tal approach. Intraoperatively, the mass was found to be 
contiguous with and adherent to the left kidney. Based on 
these intra-operative findings, the mass was not amenable 
to separation from the kidney without excision of kidney 
parenchyma. Therefore, a left partial nephrectomy was per-
formed, and no local/regional disease extension was noted. 
As shown in Figure 3(a)–(c), the mass was immediately 
adjacent to the renal capsule and had a similar histologic 
appearance to the prior core biopsy. Although the diagnosis 
of soft tissue myxoma was previously considered, immuno-
histochemical staining for CD61 was positive, highlighting 
rare large atypical cells which were consistent with mega-
karyocytes (Figure 3(d) and (e)). Given the constellation of 
clinical and histopathologic findings, a final diagnosis of 
extramedullary hematopoietic pseudotumor was ultimately 
rendered. Although the patient’s postoperative course was 
Figure 2. Results of repeat imaging studies. Axial T1 fat 
saturation post contrast image from a follow-up MRI performed 
3 months after initial presentation showing progression 
of disease in the index left perirenal mass with greater 
enhancement and increased mass effect upon the left kidney 
(white arrows).
Figure 3. Resection gross specimen and histopathology. (a) Gross resection specimen showing relationship between mass (double 
arrow) and renal parenchyma (single arrow). (b) Abundant myxoid material with scattered foci of inflammatory cells (H&E, 40×). (c) 
Relationship between the mass (left) and renal cortex (right) (H&E, 40×). (d) Focus of inflammatory cells with erythroid precursors 
(arrowhead) (H&E, 200×). (e) Larger atypical cell consistent with a megakaryocyte (arrow) (H&E, 400×).
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notable for persistent fevers and fatigue, no clear infectious 
etiology was identified. Despite a relatively prolonged 
postoperative course, the patient made a full recovery and 
was discharged home after approximately 2 weeks with 
return to baseline functional status. Following the diagnosis 
of extramedullary hematopoietic pseudotumor, the patient 
underwent a bone marrow biopsy to rule out bone marrow 
pathology. Despite the association of extramedullary 
hematopoietic pseudotumor with myelofibrosis, bone mar-
row studies showed normocellular marrow with adequate 
trilineal hematopoiesis, no significant reticulin fibrosis, and 
no increase in blasts.
Discussion
Although rare, the phenomenon of non-hepatosplenic 
extramedullary hematopoiesis (NHS-EMH) has been well 
described in the non-fetal population, but has never been 
previously reported in the A-T population. Much of the data 
pertaining to NHS-EMH come from a Mayo Clinic series 
of 27 patients between 1975 and 2002 published in 2003.9 
In the study by Koch et al.,9 NHS-EMH was most fre-
quently associated with myelofibrosis with myeloid meta-
plasia and thalassemia, though several other associations 
were also documented. The underlying connection appears 
to be chronic anemia, with an average hemoglobin concen-
tration measured in their series at 9.5 g/dL. The patient 
described in this report had a preoperative hemoglobin con-
centration consistently around 12 g/dL, suggesting that she 
should be at lower risk for EMH if the association of 
chronic anemia with NHS-EMH pseudotumor is mechanis-
tically related. However, given the risk of hematologic 
malignancy with A-T, the development of NHS-EMH may 
represent an additional manifestation of myeloid pathology 
secondary to as yet unidentified causes.
As previously noted, the connection between cancer and 
A-T is well described. Specifically, observational data sug-
gest that the cumulative incidence of cancer increases with 
age in A-T, measured at 10.4% at 10 years, 22.6% at 
20 years, 29.9% at 30 years, and 38.2% at 40 years.10 The 
most common cancers are leukemia and lymphoma, but 
there is no reported association between A-T and NHS-
EMH, which importantly is a benign tumor. A large, retro-
spective analysis published by Morrel and colleagues8 in 
1986 reviewed 263 patients with A-T and identified 52 
individual cancers that arose. Of those 52 cancers identi-
fied, the breakdown was as follows: 31 lymphoma (60%), 
14 leukemia (27%), 2 hepatocellular carcinoma (4%), 2 
carcinomas of the parotid gland (4%), 1 ovarian carcinoma 
(2%), 1 cerebellar astrocytoma (2%), and 1 uterine leio-
myosarcoma (2%). A subsequent retrospective study was 
recently completed by Suarez et al. from a French registry 
of A-T patients with similar results.10 In their cohort of 279 
patients, they identified 69 patients with cancer (25%). In 
descending order of prevalence, they noted 38 cases of 
non-Hodgkin’s lymphoma, 12 Hodgkin’s lymphoma, 11 
leukemia, 3 breast carcinoma, 2 gastric carcinoma, 2 hepa-
tocellular carcinomas, and 1 thyroid carcinoma. One patient 
with Hodgkin’s lymphoma was diagnosed with a synchro-
nous glioma. These two observational studies support the 
observation that patients with A-T are at highest risk of leu-
kemia and lymphoma, whereas solid tumors are rarer and 
tend to occur in older A-T patients, notably with an average 
age at diagnosis of 31.4 years.10
Evaluation of tumors in A-T can be difficult due to the 
underlying defect in the ATM gene and the resultant sus-
ceptibility to ionizing radiation. While there is reasonable 
concern that A-T patients should limit exposure to plain 
film X-rays and CT scans, no clear association between 
A-T and complications from exposure to diagnostic radio-
graphs has been reported,11 and it is important to avoid a 
delay in diagnosis from under-utilization of diagnostic 
imaging. Therefore, in the evaluation of A-T patients, CT 
imaging can be employed if indicated for appropriate eval-
uation and management of suspicious masses. Furthermore, 
ionizing radiation can frequently be avoided by employing 
MR imaging to evaluate and characterize suspicious lesions 
and for surgical planning. Specific to this case, T1-weighted 
images are useful in determining proximity to adjacent ret-
roperitoneal organs, while T2-weighted images can aid in 
defining local muscular invasion.12
Careful diagnostic workup is also critical for retroperi-
toneal masses, especially in A-T. Unlike the general popu-
lation where radiation therapy (RT) has a role in treating 
retroperitoneal tumors, RT is contraindicated in A-T 
because of the risk of severe and even lethal toxicities.13 
Therefore, accurate tissue diagnosis is required to guide 
the proper surgical resection and thereby oncologic out-
come with strategies to limit post-surgical morbidity and 
mortality.
In this case, prior to the final diagnosis of an extramed-
ullary hematopoietic pseudotumor, the leading diagnostic 
consideration based on the percutaneous biopsy results 
was soft tissue myxoma, another benign, mesenchymal 
neoplasm also characterized by bland spindle to stellate 
cells in myxoid stroma.14 These benign tumors are gener-
ally non-recurrent, although certain variants have demon-
strated a small risk of local, non-destructive recurrence.15 
Overall, there seems to be no correlation between A-T and 
retroperitoneal masses, although recent research has iden-
tified an interaction between the ATM protein and FUS/
TLS (currently designated as DDIT3), a translocated gene 
identified in certain human liposarcomas.16 Despite this 
molecular connection, primary sarcomas arising in A-T 
patients are limited to two case reports—notably uterine 
leiomyosarcoma17 and Epstein–Barr virus (EBV)-
associated laryngeal leiomyosarcoma.18 Though the pro-
pensity for cancer is a hallmark of A-T, the development of 
either primary sarcoma or extramedullary hematopoietic 
pseudotumor is equally rare, emphasizing the need for 
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careful multidisciplinary management of A-T patients who 
present with suspicious solid tumors.
Conclusion
Patients with A-T are at significantly increased risk of 
various cancer types, most notably leukemia and lym-
phoma. As more A-T patients live longer, other less com-
mon tumors are being identified. Given the association of 
A-T with several diseases that can lead to anemia, 
extramedullary hematopoietic pseudotumor should be on 
the differential diagnosis for atypical tumors arising in 
A-T, particularly in the retroperitoneum. Evaluation with 
comprehensive imaging modalities is essential, as is tis-
sue diagnosis to aid definitive diagnosis and surgical plan-
ning. Given the complexities of caring for patients with 
A-T, evaluation, management, and treatment should be 
carried out in specialty centers where appropriate 
resources are available.
Acknowledgements
S.J.J. was involved in conception and design, literature review, 
and writing the manuscript. T.A.P., C.P.B., M.A.D., and C.P.E. 
participated in analysis and interpretation of data and critical revi-
sion of the article. R.J.C. was involved in conception and design, 
analysis and interpretation of data, writing the manuscript, and 
critical revision of the manuscript.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with 
respect to the research, authorship, and/or publication of this 
article.
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: This 
work was supported by funding from the Dr Mark Starr Family 
Fund.
References
 1. Louis-Bar D. Sur un syndrome progress if comprenant 
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